Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics
• Pharmacology

Background:

• Tumor evolution creates context-specific molecular vulnerabilities, presenting potential therapeutic targets.
• The complexity of somatic mutations in lung tumors complicates the identification of effective intervention targets.
• Non-small cell lung cancer (NSCLC) exhibits significant genetic heterogeneity, necessitating personalized treatment approaches.

Purpose of the Study:

• To identify novel therapeutic targets in NSCLC by linking molecular vulnerabilities to predictive response indicators.
• To discover intervention opportunities that are tightly associated with specific molecular alterations in lung tumors.
• To validate target efficacies and elucidate underlying mechanisms for potential clinical translation.

Main Methods:

• Parallel screening of chemical and genetic perturbations in molecularly annotated NSCLC cell lines.
• Utilized a matched tumor/normal cell model derived from a lung adenocarcinoma patient for target identification.
• Performed in vivo validation of target efficacies and mechanism-of-action studies.

Main Results:

• Identified three distinct target/response-indicator pairings with significant frequencies (6%-16%) in the patient population.
• Discovered NLRP3 mutation/inflammasome activation-dependent FLIP addiction.
• Found co-occurring KRAS and LKB1 mutation-driven COPI addiction and selective sensitivity to a synthetic indolotriazine specified by a seven-gene expression signature.

Conclusions:

• Context-specific molecular vulnerabilities can be effectively identified through parallel screening approaches.
• Three novel therapeutic strategies for NSCLC, linked to specific molecular profiles, have been validated.
• These findings provide generalizable principles for understanding cancer cell biology and developing precision therapies.